189 patients with chronic low back pain (LBP) caused by vertebral pain syndrome were surveyed. Pain levels, measured by differential visual-analog scale, and variations of natural antibody levels to the pain bioregulators (nAbs) in blood serum at LBP were studied during 21 days. We revealed gender features of immuno-profiles: more elevated nAbs levels against opioids at women at 1st day and equal levels in both gender groups at 21 days. Generally nAbs levels remained above normal up to 21st day in most of patients despite a three-fold decrease of pain intensity. A significant decrease in nAb levels was found in 4-20% of patients, depending on the bioregulator. These observations support the hypothesis that antibodies can be a factor in the prolongation of pain, so the analysis of the dynamics of nAbs for patients with LBP can be recommended, which will be useful to predict the further course of the disease.
mHealth for pediatric chronic pain: state of the art and future directions
